CoChat
Sign Up
Cited by 771NF-κB Signaling PathwaysNatural Compounds in Disease TreatmentSignaling Pathways in Disease

The DOI matches its Crossref record; 231 of the 232 references it cites were found in a registry or an index.

Inhibiting NF-κB activation by small molecules as a therapeutic strategy

Open access
Gupta, Subash C., Sundaram, Chitra, Reuter, Simone, Aggarwal, Bharat B.·2010·Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms
DOI 10.1016/j.bbagrm.2010.05.004PMC PMC2955987
Open this paper in CoChat — free account

Abstract

Because nuclear factor-κB (NF-κB) is a ubiquitously expressed proinflammatory transcription factor that regulates the expression of over 500 genes involved in cellular transformation, survival, proliferation, invasion, angiogenesis, metastasis, and inflammation, the NF-κB signaling pathway has become a potential target for pharmacological intervention. A wide variety of agents can activate NF-κB through canonical and noncanonical pathways. Canonical pathway involves various steps including the phosphorylation, ubiquitination, and degradation of the inhibitor of NF-κB (IκBα), which leads to the nuclear translocation of the p50-p65 subunits of NF-κB followed by p65 phosphorylation, acetylation and methylation, DNA binding, and gene transcription. Thus, agents that can inhibit protein kinases, protein phosphatases, proteasomes, ubiquitination, acetylation, methylation, and DNA binding steps have been identified as NF-κB inhibitors. Because of the critical role of NF-κB in cancer and various chronic diseases, numerous inhibitors of NF-κB have been identified. In this review, however, we describe only small molecules that suppress NF-κB activation, and the mechanism by which they block this pathway.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.bbagrm.2010.05.004

Cites

231 of 231 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

2 retracted

Flagged first, then by citations

Show all 232 references

1 of the 232 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Items 601–700 of 771

Related

See all

Metadata

Authors
Gupta, S. C., Sundaram, C., Reuter, S., & Aggarwal, B. B.
Affiliations
The University of Texas MD Anderson Cancer Center (US)
Corresponding author
Aggarwal, Bharat B.
ORCID
Venue
Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms
Publisher
Elsevier BV
Published
2010-10
Volume
1799
Issue
10-12
Pages
775-787
ISSN
1874-9399 (ISSN-L)
DOI
10.1016/j.bbagrm.2010.05.004
PMC
PMC2955987
OpenAlex
W1973354681
Cited by
762
References
232
Citations by year
2026: 38 · 2025: 32 · 2024: 39 · 2023: 36 · 2022: 42 · 2021: 59 · 2020: 63 · 2019: 66 · 2018: 70 · 2017: 63 · 2016: 45 · 2015: 45 · 2014: 41 · 2013: 50 · 2012: 35
FWCI
3.26
Type
journal article
Language
en
Open access
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
National Cancer Institute (CA-16672, P01CA091844, P01CA124787, CA-124787-01A2, P30CA016672)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › NF-κB Signaling Pathways
  • Health Sciences › Medicine › Complementary and alternative medicine › Natural Compounds in Disease Treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Signaling Pathways in Disease
Keywords
NF-κB signaling, NF-κB inhibitors, small molecules, canonical NF-κB pathway, non-canonical NF-κB signaling, protein kinases, proteasome inhibitors, protein phosphatase, inflammation, cancer, chronic disease
MeSH terms
Animals, Cell Survival, Cell Transformation, Neoplastic, Gene Expression Regulation, Humans, Inflammation, Neoplasm Invasiveness, Neoplasm Metastasis, Neoplasms, Phosphorylation, Signal Transduction, NF-kappa B, Neovascularization, Physiologic, Cell Proliferation, I-kappa B Kinase

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review